Save information for later
Sign Up

Learn About Nephrogenic Diabetes Insipidus

What is the definition of Nephrogenic Diabetes Insipidus?

Arginine vasopressin resistance (previously called nephrogenic diabetes insipidus) is a disorder of water balance. The body normally balances fluid intake by releasing excess fluid in urine. However, people with arginine vasopressin resistance produce an excessive amount of urine (polyuria), which depletes the amount of water in the body. This water loss also leads to excessive thirst (polydipsia).

What are the causes of Nephrogenic Diabetes Insipidus?

The familial form of arginine vasopressin resistance can be caused by variants (also called mutations) in at least two genes that are active in the kidneys. About 90 percent of all cases of familial arginine vasopressin resistance are caused by variants in the AVPR2 gene. Most of the remaining 10 percent of cases are caused by variants in the AQP2 gene. The AVPR2 gene provides instructions for making the vasopressin V2 receptor protein, and the AQP2 gene provides instructions for of the aquaporin-2 protein. Both of these proteins work with a hormone called arginine vasopressin (AVP) to help determine how much water is released in urine.

How prevalent is Nephrogenic Diabetes Insipidus?

The prevalence of arginine vasopressin resistance is unknown, although the condition is thought to be rare. The acquired form occurs more frequently than the familial form.

Is Nephrogenic Diabetes Insipidus an inherited disorder?

When arginine vasopressin resisitance is caused by variants in the AVPR2 gene, the condition has an X-linked pattern of inheritance. The AVPR2 gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), a variant in the only copy of the gene in each cell is sufficient to cause the condition. One altered copy of the gene can cause the condition in females (who have two copies of the X chromosome) as well, although the features may be less severe than those seen in individuals with two altered copies, or there may be no signs or symptoms at all. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Who are the top Nephrogenic Diabetes Insipidus Local Doctors?
Elite in Nephrogenic Diabetes Insipidus
Elite in Nephrogenic Diabetes Insipidus
Nijmegen, GE, NL 

Peter Deen practices in Nijmegen, Netherlands. Deen is rated as an Elite expert by MediFind in the treatment of Nephrogenic Diabetes Insipidus. Their top areas of expertise are Nephrogenic Diabetes Insipidus, Diabetes Insipidus (DI), Low Sodium Level, and Milk-Alkali Syndrome.

Elite in Nephrogenic Diabetes Insipidus
Elite in Nephrogenic Diabetes Insipidus

Canisius Wilhelmina Ziekenhuis

Nijmegen, GE, NL 

Theun De Groot practices in Nijmegen, Netherlands. De Groot is rated as an Elite expert by MediFind in the treatment of Nephrogenic Diabetes Insipidus. Their top areas of expertise are Nephrogenic Diabetes Insipidus, Diabetes Insipidus (DI), Sporotrichosis, and Hypercalcemia.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Nephrogenic Diabetes Insipidus
Elite in Nephrogenic Diabetes Insipidus
Montreal, QC, CA 

Daniel Bichet practices in Montreal, Canada. Mr. Bichet is rated as an Elite expert by MediFind in the treatment of Nephrogenic Diabetes Insipidus. His top areas of expertise are Nephrogenic Diabetes Insipidus, Fabry Disease, Diabetes Insipidus (DI), and Low Sodium Level.

What are the latest Nephrogenic Diabetes Insipidus Clinical Trials?
A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1)

Summary: The purpose of this research is to study the effectiveness and safety of the medication PB in slowing the frequent urination related to tolvaptan as long-term treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), or frequent urination related to inherited nephrogenic diabetes insipidus as an inherited condition or as an acquired condition from prior treatment with lithium.

Match to trials
Find the right clinical trials for you in under a minute
Get started
National Registry of Rare Kidney Diseases (RaDaR)

Summary: The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: * Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. * Audit treatments and outcomes. An audit makes checks to see if ...

Who are the sources who wrote this article ?

Published Date: August 13, 2024
Published By: National Institutes of Health